Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Atogepant

August 2023

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Atogepant

Dosage Form: Tablet

Route: Oral

Strengths: 10 mg, 30 mg, 60 mg

Recommended Studies: Two in vivo bioequivalence studies with pharmacokinetic endpoints

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 60 mg
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: None

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 60 mg
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: None

Analyte to measure: Atogepant in plasma

Bioequivalence based on (90% CI): Atogepant

Waiver request of in vivo testing: 10 mg and 30 mg strengths based on (i) acceptable bioequivalence studies on the 60 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.

Document History: Recommended August 2023

Unique Agency Identifier: PSG_215206